Contineum Therapeutics Inc（CTNM）財務資料CTNMContineum Therapeutics Inc

Evaluating the bottom line, Contineum Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.01%, provide a clear picture of how effectively CTNM converts its operational activities into shareholder value.

In the context of the broader market, CTNM competes directly with industry leaders such as OGCP and GALT. With a market capitalization of $312.63M, it holds a significant position in the sector. When comparing efficiency, CTNM's gross margin of N/A stands against OGCP's N/A and GALT's N/A. Such benchmarking helps identify whether Contineum Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Contineum has reported consistent net losses, with a net income of -14.5 million USD in the most recent quarter, and an EPS of -0.40. The current ratio is exceptionally high at 38.00, indicating strong liquidity, but this does not offset the ongoing losses.